A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.

Date publication

mars 2024

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher , Dr VERNEREY Dewi , Mr FALCOZ Antoine

Tous les auteurs :
Moreau M, Alouani E, Flecchia C, Falcoz A, Gallois C, Auclin E, André T, Cohen R, Hollebecque A, Turpin A, Pernot S, Masson T, Di Fiore F, Dutherge M, Mazard T, Hautefeuille V, Van Laethem JL, De la Fouchardière C, Perkins G, Ben-Abdelghani M, Sclafani F, Aparicio T, Kim S, Vernerey D, Taieb J, Guimbaud R, Tougeron D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38537314

Résumé

One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer. However, few studies have compared ICI with CT in other advanced dMMR/MSI-H digestive tumors.

Mots clés

Chemotherapy, Deficient mismatch repair, Digestive cancers, Immune checkpoint inhibitors, Microsatellite instability

Référence

Eur J Cancer. 2024 03 21;202:114033